站内搜索
最新录用更多>>
高分子前药的研究进展
    点此下载全文
引用本文:韩天娇,胡玉玺,付宏征.高分子前药的研究进展[J].中国药科大学学报,2019,50(4):397-404.
Cite:HAN Tianjiao,HU Yuxi,FU Hongzheng.Research progress and consideration of polymeric prodrugs[J].J China Pharm Univ,2019,50(4):397-404.
摘要点击次数: 321
全文下载次数: 377
作者单位
韩天娇 北京大学药学院 天然药物及仿生药物国家重点实验室 
胡玉玺 国家药品监督管理局药品审评中心 
付宏征 北京大学药学院 天然药物及仿生药物国家重点实验室 
中文摘要:修饰已上市药物以改善药物存在的缺陷,是目前全球药物研发的一个重要方向。以高分子前药为基础的给药系统具有前药修饰和微纳米载药的双重优势,可以增强药物在体内、体外的稳定性,增加药物的靶向性,提高药物的生物利用度、降低药物不良反应和提高治疗效果。本文根据高分子前药的研发机制,从被动靶向、主动靶向、触发释药和协同给药进行综述,探讨该类药物的研发现状及所面临的问题,并对此给出适当可行的解决方案。
中文关键词:高分子前药  被动靶向  主动靶向  触发释药  协同给药
 
Research progress and consideration of polymeric prodrugs
Abstract:Currently the available therapies cannot satisfy all the clinical requirements, therefore advanced technologies are urgently demanded. Delivery system the polymeric prodrug based has both advantages of prodrug strategy and nanoparticle drug delivery strategy. The system can improve the drug bioavailability, enhance the drug stability, and make the drug targeting system more effective. The system can reduce the side effects and improve the therapeutic effect of drug. According to the mechanism of this drug system, passive targeting, active targeting, triggered release and co-administration were reviewed. Finally, the research prospects and issues in this field were pointed out.
keywords:polymeric prodrugs  passive targeting  active targeting  triggered release  co-administration
查看全文  查看/发表评论  下载PDF阅读器
分享按钮